Clinical Trial

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Protocol Amendment History 1 change
notable Trial sites expanded: 3 -> 17 locations 2026-07-11
Trial Details
NCT Number NCT07678593
Lead Sponsor Genfleet Therapeutics (Shanghai) Inc.
Conditions Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
Enrollment 222 participants
Start Date 2026-09
Primary Completion 2027-11 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-10